Literature DB >> 16175654

Routine testing for mismatch repair deficiency in sporadic colorectal cancer is justified.

Robyn Lynne Ward1, Jenny Turner, Rachel Williams, Brita Pekarsky, Deborah Packham, Marija Velickovic, Alan Meagher, Terence O'Connor, Nicholas John Hawkins.   

Abstract

This study prospectively examines the accuracy of immunohistochemical staining in the identification of mismatch repair defective (MMRD) colorectal cancer in routine clinical practice. The potential impact of this information on decisions regarding adjuvant treatment and germline testing were quantified. A consecutive series of fresh tissue (836 cancers) was obtained from 786 individuals undergoing curative surgery for colorectal cancer at one institution. As part of normal practice, each tumour was screened for the expression of MLH1 and MSH2 by immunohistochemical staining (IHC) and relevant clinicopathological details were documented. Microsatellite instability (MSI) was assessed using standard markers. Overall, 108 (13%) tumours showed loss of staining for either MLH1 (92 tumours) or MSH2 (16 tumours). The positive predictive value of mismatch repair IHC when used alone in the detection of MSI tumours was 88%, and the negative predictive value was 97%. Specificity and positive predictive value were improved by correlation with microsatellite status. Tumour stage (HR 3.5, 95% CI 2.0-6.0), vascular space invasion (HR 1.9, 95% CI 1.2-3.0) and mismatch repair deficiency (HR 0.2, 95% CI 0.05-0.87) were independent prognostic factors in stages II and III disease. Screening by mismatch repair IHC could reasonably have been expected to prevent ineffective treatment in 3.6% of stage II and 7.6% of stage III patients. The frequency of germline mismatch repair mutations was 0.8%, representing six unsuspected hereditary non-polyposis colorectal cancer (HNPCC) cases. Routine screening of colorectal cancers by mismatch repair IHC identifies individuals at low risk of relapse, and can prevent unnecessary adjuvant treatments in a significant number of individuals. Abnormal immunohistochemistry should be confirmed by microsatellite testing to ensure that false-positive results do not adversely impact on treatment decisions. Copyright 2005 Pathological Society of Great Britain and Ireland.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16175654     DOI: 10.1002/path.1851

Source DB:  PubMed          Journal:  J Pathol        ISSN: 0022-3417            Impact factor:   7.996


  15 in total

1.  Introducing new health interventions: diagnostics is the Cinderella of health technology assessment.

Authors:  Peter N Furness
Journal:  BMJ       Date:  2006-01-28

2.  Predictive value of microsatellite instability for benefit from adjuvant fluorouracil chemotherapy in colorectal cancer.

Authors:  B Iacopetta; T Watanabe
Journal:  Gut       Date:  2006-11       Impact factor: 23.059

Review 3.  Colorectal cancer molecular profiling: from IHC to NGS in search of optimal algorithm.

Authors:  Larissa V Furtado; Wade S Samowitz
Journal:  Virchows Arch       Date:  2017-05-27       Impact factor: 4.064

Review 4.  Rate of dissemination and prognosis in early and advanced stage colorectal cancer based on microsatellite instability status: systematic review and meta-analysis.

Authors:  James W T Toh; Kevin Phan; Faizur Reza; Pierre Chapuis; Kevin J Spring
Journal:  Int J Colorectal Dis       Date:  2021-02-18       Impact factor: 2.571

5.  ARID1A expression in gastric adenocarcinoma: clinicopathological significance and correlation with DNA mismatch repair status.

Authors:  Ryo Inada; Shigeki Sekine; Hirokazu Taniguchi; Hitoshi Tsuda; Hitoshi Katai; Toshiyoshi Fujiwara; Ryoji Kushima
Journal:  World J Gastroenterol       Date:  2015-02-21       Impact factor: 5.742

6.  Mismatch repair protein expression in colorectal cancer.

Authors:  Elrasheid A H Kheirelseid; Nicola Miller; Kah Hoong Chang; Catherine Curran; Emer Hennessey; Margaret Sheehan; Michael J Kerin
Journal:  J Gastrointest Oncol       Date:  2013-12

7.  Somatic mutation of MutYH in Tunisian patients with sporadic colorectal cancer.

Authors:  Karim Bougatef; Raja Marrakchi; Nadia Kourda; Yannick Blondeau Ben Lahely; Sarra Baltagi Jileni; Houssein K El Khil; Florent Soubrier; Amel Ben Ammar Elgaaied
Journal:  J Clin Lab Anal       Date:  2007       Impact factor: 2.352

8.  Heterogeneous staining for mismatch repair proteins during population-based prescreening for hereditary nonpolyposis colorectal cancer.

Authors:  Natasha Watson; Fabienne Grieu; Melinda Morris; Jennet Harvey; Colin Stewart; Lyn Schofield; Jack Goldblatt; Barry Iacopetta
Journal:  J Mol Diagn       Date:  2007-07-25       Impact factor: 5.568

9.  Microsatellite instability in Ewing tumor is not associated with loss of mismatch repair protein expression.

Authors:  I Alldinger; K L Schaefer; D Goedde; L Ottaviano; U Dirksen; A Ranft; H Juergens; H E Gabbert; W T Knoefel; C Poremba
Journal:  J Cancer Res Clin Oncol       Date:  2007-05-25       Impact factor: 4.553

10.  Worldwide variation in lynch syndrome screening: case for universal screening in low colorectal cancer prevalence areas.

Authors:  George Kunnackal John; Vipin Das Villgran; Christine Caufield-Noll; Francis Giardiello
Journal:  Fam Cancer       Date:  2020-09-11       Impact factor: 2.375

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.